ReviewClinical kidney journal2021

Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis.

Cheng Xue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.